AMGN up +0.14% percent right now. $AMGN High is at 163.86

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
AMGN up +0.14% percent right now. $AMGN High is at 163.86 and the Low 162.02 with current volume of 1,088,689.

Recent News posted below.

AMGN Amgen Inc Recent Headline News

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
PR Newswire - 26 mins ago
Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). A significantly greater proportion of patients treated with brodalumab also achieved clear or almost clear skin at week 12 compared with placebo, according to the static Physician Global Assessment (sPGA 0 or 1). All key secondary endpoints comparing brodalumab with Stelara and placebo were also met.
AZN: 74.20 (+0.99), AMGN: 162.42 (-0.67)

Midday Glance: Biotechnology companies
AP - 2 hrs 35 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16)

Amgen Fights To Protect Neupogen's Exclusivity
Tim Harrison - at Seeking Alpha - Tue Nov 11, 11:31AM CST

AMGN: 162.42 (-0.67)

NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:50AM CST
NPS Pharma (NPSP) reported a loss of 2 cents per share in the third quarter of 2014, wider than the year-ago loss of 1 cent per share.
AUXL: 32.63 (-0.07), NPSP: 29.41 (+2.50), AMGN: 162.42 (-0.67), BIOD: 1.57 (+0.07)

Early Glance: Biotechnology companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16)

Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 382.55 (-4.72), YHOO: 49.05 (-0.36), AMZN: 312.01 (+6.90), BIIB: 324.59 (-3.28), VRTX: 117.49 (+0.55), FEYE: 32.85 (+0.46), LNKD: 231.00 (+1.75), EBAY: 54.19 (+0.30), GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), ABBV: 63.85 (+0.06), REGN: 398.36 (+12.39), CELG: 107.85 (-0.16)

Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST

MRK: 59.37 (+0.56), AZN: 74.20 (+0.99), AMGN: 162.42 (-0.67), TEVA: 58.19 (+0.15), THRX: 12.93 (-0.51), GSK: 45.96 (+0.80), SNY: 47.14 (+0.95), REGN: 398.36 (+12.39), NVS: 92.77 (+0.14)

Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 87.93 (+0.22), VRX: 130.03 (+2.04), ALXN: 194.92 (-0.88), AMGN: 162.42 (-0.67), MYL: 53.51 (-0.44), ILMN: 187.88 (-0.39), CELG: 107.85 (-0.16)

Final Glance: Biotechnology companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 108.01 (+0.99), AMGN: 162.42 (-0.67), CELG: 107.85 (-0.16)

Look for Shares of Amgen to Potentially Pullback after Yesterday's 1.77% Rise
Comtex SmarTrend(R) - Mon Nov 10, 3:46PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $160.50 to a high of $163.20. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $162.25 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.42 (-0.67)

Amgen Set to Possibly Pullback After Yesterday's Rally of 1.77%
Comtex SmarTrend(R) - Mon Nov 10, 3:45PM CST
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $160.50 to a high of $163.20. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $162.25 on volume of 3.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 162.42 (-0.67)

Post Earnings Update: Amgen Has Climbed 8.1% Higher in Past 2 Weeks (AMGN)
Comtex SmarTrend(R) - Mon Nov 10, 12:30PM CST
Two weeks ago on October 27th, 2014 Amgen (NASDAQ:AMGN) reported earnings and analysts, on average, expected earnings of $2.11 on sales of $5.0 billion. The company actually reported EPS of $2.30 on sales of $5.0 billion, beating EPS estimates by $0.19 and beating revenue estimates by $72.4 million. Shares of Amgen have climbed from $148.20 to $160.25, representing a gain of 8.1% since the company reported earnings 14 days ago.
AMGN: 162.42 (-0.67)

Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (-0.01), IMGN: 10.09 (+0.14), AMGN: 162.42 (-0.67), LLY: 67.85 (-0.50), ONTX: 4.85 (-0.01), BMY: 58.72 (-0.09), GSK: 45.96 (+0.80), OXGN: 1.92 (-0.06), XLRN: 33.72 (+1.46), KPTI: 43.00 (+0.32), NVS: 92.77 (+0.14)

FDA OK with Amgen's BLA for cholesterol-lowering drug
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:02AM CST

AMGN: 162.42 (-0.67)

VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 107.29 (-1.66), ABMD: 33.09 (+0.10), JNJ: 108.91 (+0.09), AMGN: 162.42 (-0.67), EXAS: 22.45 (-0.15), ARAY: 7.02 (+0.12), HOLX: 26.61 (+0.06), PBYI: 240.35 (-4.44)

FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
PR Newswire - Mon Nov 10, 8:15AM CST
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
AMGN: 162.42 (-0.67)

Ziarco Raises $33.1 Million in Series B Financing
GlobeNewswire - Mon Nov 10, 6:07AM CST
Ziarco Group Ltd, a biopharmaceutical company focusing on inflammatory skin diseases, today announced the completion of a $33.1 million Series B financing round. New Enterprise Associates, Inc. (NEA) and Lundbeckfond Ventures co-led the round with new investor Amgen Ventures joining the existing investors BVF Partners L.P. and Pfizer Venture Investments. Ed Mathers, partner at NEA, has joined Ziarco's board of directors as Chairman. Johan Kordel, senior partner at Lundbeckfond Ventures, has also joined the board.
AMGN: 162.42 (-0.67)

Hess Corporation Tops Best Value Long-Term Bond Ranking
Donald van Deventer - at Seeking Alpha - Sun Nov 09, 8:58AM CST

PSX: 73.64 (-0.86), SCCO: 30.23 (+0.35), SWY: 34.90 (+0.01), HES: 83.81 (unch), UTX: 108.26 (-0.74), RTN: 103.74 (+0.22), WMT: 79.01 (-0.43), TAP: 76.21 (-0.44), AMGN: 162.42 (-0.67), COP: 71.75 (+0.15), SWK: 95.83 (-0.05), DO: 36.64 (-0.83), IBM: 163.30 (-0.19), CVS: 89.76 (+0.57), CAT: 102.53 (+0.32), PPG: 205.26 (-1.01), WAG: 67.50 (-0.28)

Medical Device Companies Were Election Day Winners
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 11:00AM CST
Source: Library of Congress The shift in power in Washington may have big implications for medical device companies if legislation is rekindled to ditch the 2.3% medical device tax. That tax, enacted as part of Obamacare to help fund the cost of...
BIIB: 324.59 (-3.28), MDT: 68.99 (+0.28), AMGN: 162.42 (-0.67), SYK: 88.68 (+0.24)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 124

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 131

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 189

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 67

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 19

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 29

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 55

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 81

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 107

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 33

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Unique Features of Ontomir (OTM) on BitMart

Updated Category News Views 315

Ontomir (OTM) Launches on BitMart Exchange In the world of digital assets, BitMart, a leading global trading platform, has recently showcased its commitment to innovation by announcing the listing of Ontomir (OTM). This launch marks a significant milestone for Ontomir, as the OTM/USDT trading pair becomes available, creating new opportunities for investors. Understanding...

Continue Reading
Vanguard Introduces New Actively Managed Bond ETF for Investors

Updated Category News Views 199

Vanguard Unveils a New Actively Managed Bond ETF Today, Vanguard has proudly introduced the Vanguard Multi-Sector Income Bond ETF (VGMS), a new offering in the realm of actively managed fixed-income exchange-traded funds (ETFs). This innovative product is supervised by the Vanguard Fixed Income Group, known for its extensive expertise in the field. A Commitment to...

Continue Reading
U.S. Markets Experience Mixed Trading Amid Oil Inventory Declines

Updated Category News Views 95

Mixed Performance of U.S. Stocks U.S. stocks displayed a mixed performance during the mid-week trading session, with the S&P 500 edging slightly lower. The markets reacted to various financial reports and inventory levels that influenced trader sentiments. Index Updates The Dow Jones recorded a modest increase, up by 0.08% to 42,267.94. In contrast, the NASDAQ saw a...

Continue Reading
Alignment Healthcare's Strategic Presentation Insights

Updated Category News Views 162

Alignment Healthcare's Upcoming Presentation Alignment Healthcare, Inc. (NASDAQ: ALHC) is making waves in the healthcare sector as it gears up for an important presentation at a renowned healthcare conference. This significant event will take place in January, showcasing the company's commitment to transforming senior care. The Conference Details On January 15, 2025, at...

Continue Reading
Unveiling Talen Energy's Options Trading Trends and Insights

Updated Category News Views 185

Insights into Talen Energy's Recent Options Activity Whales, those significant players in the financial markets, have recently shown a strong bullish interest in Talen Energy. This interest is reflected in a notable increase in options trading activity regarding Talen Energy (NASDAQ: TLN). Understanding the Trading Trends for TLN Within the recent options trading history...

Continue Reading